Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC) today and set a price target of $72.00. The company’s shares closed last Monday at $35.95.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 5.9% and a 41.1% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
NextCure has an analyst consensus of Strong Buy, with a price target consensus of $69.00.
See today’s analyst top recommended stocks >>
Based on NextCure’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.01 million and GAAP net loss of $10.93 million. In comparison, last year the company had a GAAP net loss of $6.86 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NXTC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.
